MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
MARAVAI LIFESCIENCES HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.99+0.20 (+2.95%)
Close on Oct 19, 2026
- Market cap
- $1.03B
- P/E (TTM)
- –
- Dividend yield
- –
Maravai Lifesciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Market Cap | $1.82B | $166.30M |
| Enterprise Value | $2.04B | $88.19M |
| PS Ratio | 8.69 | 3.65 |
| PB Ratio | 8.87 | 2.03 |
Enterprise value
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| EV / Sales | 9.79 | 2.51 |
Income (trailing twelve months)
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Revenue | $208.78M | $58.34M |
| Gross Profit | $72.85M | $105.94M |
| Operating Income | -$117.07M | -$21.40M |
| Pretax Income | -$136.49M | -$14.34M |
| Net Income | -$77.39M | -$22.46M |
| EBITDA | -$117.07M | -$16.91M |
| EPS (Diluted) | -$0.53 | -$0.83 |
Margins
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Gross Margin | 34.9% | 52.9% |
| Operating Margin | -56.1% | -44.0% |
| Pretax Margin | -65.4% | -13.3% |
| Profit Margin | -37.1% | -40.2% |
| EBITDA Margin | -56.1% | -30.2% |
| FCF Margin | -17.2% | -9.27% |
Returns
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -32.9% | -53.2% |
| Return on Assets (ROA) | -10.3% | -40.9% |
| Return on Invested Capital (ROIC) | -32.4% | -32.4% |
| Return on Capital Employed (ROCE) | -20.7% | -38.1% |
Growth
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -5.03% | 5.96% |
| Revenue Growth (3Y CAGR) | -40.5% | 2.25% |
| Revenue Growth (5Y CAGR) | -8.15% | 6.48% |
Balance sheet
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $70.09M | $61.43M |
| Total Debt | $147.11M | $118.52M |
| Net Cash (Debt) | -$77.01M | $15.35M |
| Net Cash Per Share | -$0.30 | $0.66 |
| Equity (Book Value) | $204.62M | $49.09M |
| Book Value Per Share | $0.79 | $1.37 |
| Tangible Book Value | -$63.18M | $23.52M |
| Working Capital | $117.24M | $76.81M |
Financial position
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Current Ratio | 4.05 | 3.34 |
| Quick Ratio | 2.63 | 2.44 |
| Debt / Equity | 0.72 | 0.52 |
| Interest Coverage | -4.89 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$25.26M | -$12.35M |
| Capital Expenditures | -$10.58M | -$1.08M |
| Free Cash Flow | -$35.84M | -$20.22M |
| FCF Per Share | -$0.14 | -$0.42 |
Efficiency
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Asset Turnover | 0.28 | 0.39 |
| Inventory Turnover | 3.09 | 2.70 |
| Revenue Per Employee | $479.94K | $404.87K |
| Profits Per Employee | -$177.90K | -$703.34K |
| Employee Count | 435 | 74 |
Dividends and yields
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Earnings Yield | -4.26% | -23.3% |
| FCF Yield | -1.97% | -8.72% |
Shares
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Shares Outstanding | 259,674,000 | 58,127,000 |
| Shares Change (YoY) | 2.30% | 10.9% |
| Float | 119,063,000 | 49,136,700 |
| Shares Held by Insiders | 54.1% | 11.6% |
| Shares Held by Institutions | 55.5% | 59.4% |
Taxes
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Income Tax | -$408.00K | $79.87K |
Scores
| Measure | Maravai Lifesciences | Industry median |
|---|---|---|
| Altman Z-Score | 4.31 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Maravai Lifesciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.